These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26471484)

  • 1. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
    de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH; Morgan GJ; Owen RG
    Haematologica; 2016 Feb; 101(2):e69-71. PubMed ID: 26471484
    [No Abstract]   [Full Text] [Related]  

  • 2. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
    Landgren O; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
    Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
    Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.
    Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A
    Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant induction regimens for multiple myeloma.
    Vesole DH; Siegel DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):200-1. PubMed ID: 25534538
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
    Vij R; Kumar S; Zhang MJ; Zhong X; Huang J; Dispenzieri A; Abidi MH; Bird JM; Freytes CO; Gale RP; Kindwall-Keller TL; Kyle RA; Landsburg DJ; Lazarus HM; Munker R; Roy V; Sharma M; Vogl DT; Wirk B; Hari PN
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):335-41. PubMed ID: 25445028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
    Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
    Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
    Hu B; Thall P; Milton DR; Sasaki K; Bashir Q; Shah N; Patel K; Popat U; Hosing C; Nieto Y; Lin P; Delgado R; Jorgensen J; Manasanch E; Weber D; Thomas S; Orlowski RZ; Champlin R; Qazilbash MH
    Leuk Lymphoma; 2019 Feb; 60(2):442-452. PubMed ID: 30032678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
    Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Murray K; Culham M; Luider J; Fourie T; Rashid-Kolvear F; Bahlis NJ
    Leuk Lymphoma; 2016; 57(4):973-6. PubMed ID: 26450458
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes.
    Kumar L; Gundu N; Kancharia H; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma O; Biswas A; Kumar R; Thulkar S; Mallick S;
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):80-90.e5. PubMed ID: 33129746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction therapy for multiple myeloma: more is not necessarily better!
    Kumar L; Ganesan P
    Br J Haematol; 2018 Jul; 182(1):7-8. PubMed ID: 29676443
    [No Abstract]   [Full Text] [Related]  

  • 14. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
    Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
    Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
    Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
    Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in a Patient with Concomitant Porphyria Cutanea Tarda.
    Mohamed ZA; Pelletier S; Vintze-Geoffrion A; Lagacé-Nadon S; Olney HJ; Adam JP
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e264-e266. PubMed ID: 33390349
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
    Huang W; Li J; Li H; Kang W; Bo J; Zhao Y; Gao C; Zhou D; Yu L
    Leuk Lymphoma; 2012 Dec; 53(12):2507-10. PubMed ID: 22512306
    [No Abstract]   [Full Text] [Related]  

  • 19. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
    Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
    Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
    Garderet L; Sbianchi G; Iacobelli S; Blaise D; Byrne JL; Remenyi P; Apperley JF; Touzeau C; Isaksson C; Browne P; Mayer J; Lenhoff S; Gonzalez Muniz S; Parody Porras R; Basak G; Poire X; Trneny M; Nagler A; Michieli M; Tanase A; Koster L; Hayden PJ; Beksac M; Schönland S; Yakoub-Agha I
    Eur J Haematol; 2021 May; 106(5):708-715. PubMed ID: 33580608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.